메뉴 건너뛰기




Volumn 7, Issue 12, 2017, Pages 1404-1419

Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BETA3 INTEGRIN; C REACTIVE PROTEIN; CASPASE 3; CD19 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FERRITIN; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 6; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN P55; TOCILIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; LYMPHOCYTE ANTIGEN RECEPTOR;

EID: 85037359093     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-17-0698     Document Type: Article
Times cited : (990)

References (25)
  • 1
    • 84896335556 scopus 로고    scopus 로고
    • Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
    • Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
    • (2014) Sci Transl Med , vol.6
    • Davila, M.L.1    Riviere, I.2    Wang, X.3    Bartido, S.4    Park, J.5    Curran, K.6
  • 2
    • 84923118622 scopus 로고    scopus 로고
    • Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
    • Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540–9.
    • (2015) J Clin Oncol , vol.33 , pp. 540-549
    • Kochenderfer, J.N.1    Dudley, M.E.2    Kassim, S.H.3    Somerville, R.P.4    Carpenter, R.O.5    Stetler-Stevenson, M.6
  • 4
    • 84940881287 scopus 로고    scopus 로고
    • Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
    • Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015;7:303ra139.
    • (2015) Sci Transl Med , vol.7
    • Porter, D.L.1    Hwang, W.T.2    Frey, N.V.3    Lacey, S.F.4    Shaw, P.A.5    Loren, A.W.6
  • 6
    • 84988805188 scopus 로고    scopus 로고
    • Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptormodified T cells
    • Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptormodified T cells. Sci Transl Med 2016;8:355ra116.
    • (2016) Sci Transl Med , vol.8
    • Turtle, C.J.1    Hanafi, L.A.2    Berger, C.3    Hudecek, M.4    Pender, B.5    Robinson, E.6
  • 7
    • 84988984072 scopus 로고    scopus 로고
    • CD19-targeted chimeric antigen receptor-modified T cell immunotherapy for B cell malignancies
    • Turtle CJ, Riddell SR, Maloney DG. CD19-targeted chimeric antigen receptor-modified T cell immunotherapy for B cell malignancies. Clin Pharmacol Ther 2016;100:252–8.
    • (2016) Clin Pharmacol Ther , vol.100 , pp. 252-258
    • Turtle, C.J.1    Riddell, S.R.2    Maloney, D.G.3
  • 8
    • 84977477922 scopus 로고    scopus 로고
    • Toxicities of chimeric antigen receptor T cells: Recognition and management
    • Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016;127:3321–30.
    • (2016) Blood , vol.127 , pp. 3321-3330
    • Brudno, J.N.1    Kochenderfer, J.N.2
  • 9
    • 84904097189 scopus 로고    scopus 로고
    • Current concepts in the diagnosis and management of cytokine release syndrome
    • Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188–95.
    • (2014) Blood , vol.124 , pp. 188-195
    • Lee, D.W.1    Gardner, R.2    Porter, D.L.3    Louis, C.U.4    Ahmed, N.5    Jensen, M.6
  • 10
    • 84882637960 scopus 로고    scopus 로고
    • Biomarkers of endothelial activation/dysfunction in infectious diseases
    • Page AV, Liles WC. Biomarkers of endothelial activation/dysfunction in infectious diseases. Virulence 2013;4:507–16.
    • (2013) Virulence , vol.4 , pp. 507-516
    • Page, A.V.1    Liles, W.C.2
  • 11
    • 84931291702 scopus 로고    scopus 로고
    • VWF excess and ADAMTS13 deficiency: A unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP
    • Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost 2015;113:708–18.
    • (2015) Thromb Haemost , vol.113 , pp. 708-718
    • Schwameis, M.1    Schörgenhofer, C.2    Assinger, A.3    Steiner, M.M.4    Jilma, B.5
  • 13
    • 84958095360 scopus 로고    scopus 로고
    • Highdensity lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion
    • Chung DW, Chen J, Ling M, Fu X, Blevins T, Parsons S, et al. Highdensity lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. Blood 2016;127:637–45.
    • (2016) Blood , vol.127 , pp. 637-645
    • Chung, D.W.1    Chen, J.2    Ling, M.3    Fu, X.4    Blevins, T.5    Parsons, S.6
  • 15
    • 77649225653 scopus 로고    scopus 로고
    • The blood brain barrier and the role of cytokines in neuropsychiatry
    • Yarlagadda A, Alfson E, Clayton AH. The blood brain barrier and the role of cytokines in neuropsychiatry. Psychiatry (Edgmont) 2009;6:18–22.
    • (2009) Psychiatry (Edgmont) , vol.6 , pp. 18-22
    • Yarlagadda, A.1    Alfson, E.2    Clayton, A.H.3
  • 18
    • 84926099033 scopus 로고    scopus 로고
    • Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study
    • Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16:57–66.
    • (2015) Lancet Oncol , vol.16 , pp. 57-66
    • Topp, M.S.1    Gökbuget, N.2    Stein, A.S.3    Zugmaier, G.4    O’Brien, S.5    Bargou, R.C.6
  • 19
    • 85018417861 scopus 로고    scopus 로고
    • Tumour ischaemia by interferon-γ resembles physiological blood vessel regression
    • Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, et al. Tumour ischaemia by interferon-γ resembles physiological blood vessel regression. Nature 2017;545:98–102.
    • (2017) Nature , vol.545 , pp. 98-102
    • Kammertoens, T.1    Friese, C.2    Arina, A.3    Idel, C.4    Briesemeister, D.5    Rothe, M.6
  • 20
    • 80055079785 scopus 로고    scopus 로고
    • Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: Long-term results of the HLH-94 treatment protocol
    • Trottestam H, Horne A, Aricò M, Egeler RM, Filipovich AH, Gadner H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 2011;118:4577–84.
    • (2011) Blood , vol.118 , pp. 4577-4584
    • Trottestam, H.1    Horne, A.2    Aricò, M.3    Egeler, R.M.4    Filipovich, A.H.5    Gadner, H.6
  • 21
    • 84963704157 scopus 로고    scopus 로고
    • Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy
    • Chen F, Teachey DT, Pequignot E, Frey N, Porter D, Maude SL, et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J Immunol Methods 2016;434:1–8.
    • (2016) J Immunol Methods , vol.434 , pp. 1-8
    • Chen, F.1    Teachey, D.T.2    Pequignot, E.3    Frey, N.4    Porter, D.5    Maude, S.L.6
  • 22
    • 58149154996 scopus 로고    scopus 로고
    • Mechanisms and pathologic significances in increase in serum interleukin- 6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
    • Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin- 6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959–64.
    • (2008) Blood , vol.112 , pp. 3959-3964
    • Nishimoto, N.1    Terao, K.2    Mima, T.3    Nakahara, H.4    Takagi, N.5    Kakehi, T.6
  • 23
    • 84989908039 scopus 로고    scopus 로고
    • Dysregulation of angiopoietin-1 plays a mechanistic role in the pathogenesis of cerebral malaria
    • Higgins SJ, Purcell LA, Silver KL, Tran V, Crowley V, Hawkes M, et al. Dysregulation of angiopoietin-1 plays a mechanistic role in the pathogenesis of cerebral malaria. Sci Transl Med 2016;8:358ra128.
    • (2016) Sci Transl Med , vol.8
    • Higgins, S.J.1    Purcell, L.A.2    Silver, K.L.3    Tran, V.4    Crowley, V.5    Hawkes, M.6
  • 24
    • 84959349563 scopus 로고    scopus 로고
    • Angiopoietin- 2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling
    • Gurnik S, Devraj K, Macas J, Yamaji M, Starke J, Scholz A, et al. Angiopoietin- 2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling. Acta Neuropathol 2016;131:753–73.
    • (2016) Acta Neuropathol , vol.131 , pp. 753-773
    • Gurnik, S.1    Devraj, K.2    Macas, J.3    Yamaji, M.4    Starke, J.5    Scholz, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.